Respiratory disease is any condition that affects the airways, lungs, or the structures that help you breathe. These diseases range from short-lived infections like pneumonia to lifelong conditions like asthma and COPD. In 2023, chronic respiratory diseases alone accounted for roughly 569 million cases and 4.2 million deaths worldwide, making them one of the leading causes of illness and death globally.
How the Respiratory System Is Organized
Your respiratory system has two main zones, and where a disease strikes determines a lot about how it feels and how serious it is. The upper airway includes your nose, the back of your throat (nasopharynx), and your voice box (larynx). Common colds, sinus infections, and laryngitis all live here. They’re usually uncomfortable but not dangerous.
Below those structures sits the trachea, which splits into two main airways, one for each lung. These keep branching into progressively smaller tubes until they reach the tiniest passages, called terminal bronchioles, which are only about one millimeter wide. At the very end are the air sacs where oxygen passes into your blood and carbon dioxide passes out. Lower respiratory diseases, the ones affecting these deeper structures, tend to be more serious because they directly interfere with gas exchange.
Obstructive vs. Restrictive Disease
Doctors broadly sort chronic lung conditions into two categories based on what’s going wrong mechanically.
Obstructive diseases make it hard to push air out. The airways narrow or become blocked, trapping air inside the lungs. People with obstructive disease often describe it as trying to breathe out through a straw. Over time the lungs can actually get larger because so much air stays trapped. Asthma and COPD are the most common examples. In asthma, irritants or allergens trigger swelling and tightening of the airways. In COPD, long-term damage (usually from smoking) permanently narrows the airways and destroys air sacs.
Restrictive diseases make it hard to breathe in. Scarring, inflammation, or thickening of lung tissue prevents the lungs from expanding fully. Because the tissue itself is damaged, oxygen and carbon dioxide have trouble passing through it into and out of the bloodstream. Pulmonary fibrosis is the best-known example: lung tissue gradually scars over, making each breath shallower and harder to take.
This distinction matters because it shapes everything from the breathing tests used for diagnosis to the treatments that work best.
Common Chronic Respiratory Diseases
Asthma
Asthma is driven by an overactive immune response in the airways. When you inhale a trigger (pollen, dust, cold air, exercise), immune cells in the lining of your airways release chemicals like histamine and other inflammatory signals. These cause the airway muscles to tighten and the lining to swell, making the passages much narrower. In the hours that follow, a second wave of immune cells floods the area and keeps the inflammation going.
Over years of repeated flare-ups, the airway walls can physically remodel. The smooth muscle layer thickens, extra collagen builds up, and the passages become permanently narrower. This is why controlling inflammation early and consistently is central to modern asthma management. Current guidelines recommend that every person with asthma use an inhaler containing an anti-inflammatory steroid component rather than relying on a quick-relief bronchodilator alone. Treatment is stepped up gradually: if symptoms persist on a low dose, the maintenance dose increases, and additional medications can be layered on for severe cases.
COPD
Chronic obstructive pulmonary disease is typically a disease of accumulated damage. Most cases trace back to years of tobacco smoke exposure, though long-term air pollution and occupational dust exposure also contribute. The airways become chronically inflamed, excess mucus clogs the passages, and the walls of the air sacs break down. Unlike asthma, the airflow limitation in COPD is largely irreversible.
Symptoms build slowly. Many people dismiss years of a “smoker’s cough” or mild breathlessness before the disease is diagnosed. By the time airflow is noticeably limited, significant lung tissue has already been lost.
Pulmonary Fibrosis
In pulmonary fibrosis, scar tissue gradually replaces normal lung tissue. The lungs become stiff and can’t inflate properly, and the thickened tissue acts as a barrier to gas exchange. Breathing feels progressively more difficult, especially during physical activity. The cause is sometimes identifiable (occupational dust, certain medications, autoimmune disease) but in many cases remains unknown.
Common Acute Respiratory Diseases
Pneumonia
Pneumonia is an infection that fills the air sacs with fluid or pus, making it painful to breathe and limiting oxygen intake. Where you pick it up matters clinically. Community-acquired pneumonia, the kind you catch in everyday life, is most often caused by a type of bacteria called pneumococcus. Hospital-acquired pneumonia tends to involve different, often harder-to-treat bacteria like staphylococcus or certain gut-related organisms. Viral pneumonia, including cases caused by influenza and COVID-19, can range from mild to life-threatening.
Tuberculosis
Tuberculosis exists in two forms. In latent TB, the bacteria live in your body but are kept in check by your immune system. You have no symptoms and can’t spread it to others. In active TB, the bacteria multiply, usually in the lungs, causing a persistent cough lasting three weeks or more, chest pain, coughing up blood or phlegm, fatigue, weight loss, fever, and night sweats. The distinction between latent and active TB is critical because only active disease is contagious and symptomatic.
Major Risk Factors
Smoking and air pollution are the two dominant environmental drivers. A large prospective study found that smoking and air pollution together accounted for over 40% of lung cancer, pulmonary fibrosis, and COPD cases. The risk isn’t simply additive: people with a high genetic predisposition who were also exposed to both smoking and high air pollution faced dramatically amplified risk compared to what either factor would cause alone.
Specific air pollutants that matter include fine particulate matter smaller than 2.5 micrometers (PM2.5), coarser particles up to 10 micrometers, and nitrogen dioxide. These are common in vehicle exhaust, industrial emissions, and wildfire smoke. Secondhand tobacco smoke, even as little as one hour per week of exposure, was linked to increased risk of chronic respiratory disease in the same research.
Occupational exposures round out the picture. Coal dust, asbestos, silica, grain dust, and chemical fumes all damage lung tissue with prolonged contact. Genetic factors also play a role. Some people inherit traits that make their lungs more vulnerable to damage from the same environmental exposures that others tolerate with less harm.
How Respiratory Disease Is Diagnosed
The cornerstone test is spirometry, a straightforward breathing test that measures how much air you can force out of your lungs and how quickly. You take a deep breath and blow as hard and fast as you can into a mouthpiece. The test produces two key numbers: the total volume of air you exhale (forced vital capacity) and the volume you exhale in the first second (FEV1). The ratio between those two numbers helps determine whether your breathing problem is obstructive, restrictive, or normal.
A low ratio, meaning you can’t push air out quickly relative to your total lung volume, points toward obstructive disease. A proportionally reduced total volume suggests restrictive disease. Another test, called diffusion capacity testing, measures how well gases cross from the air sacs into your blood. This is particularly useful for detecting diseases that damage the thin membrane where gas exchange happens, like pulmonary fibrosis or emphysema.
Beyond breathing tests, chest X-rays and CT scans visualize structural damage, infection, or fluid in the lungs. For infections like TB and pneumonia, sputum cultures and blood tests help identify the specific organism involved.
Global Trends
Despite the enormous number of people affected, the global death rate from chronic respiratory diseases has actually dropped about 26% since 1990. Better pollution controls, declining smoking rates in many countries, and improved treatments all contribute. But the picture isn’t uniformly positive. Interstitial lung diseases like pulmonary fibrosis and pulmonary sarcoidosis have been increasing, partially offsetting gains in other areas. Low- and middle-income countries continue to bear a disproportionate burden, driven by indoor air pollution from cooking fuels, limited healthcare access, and higher smoking rates in some regions.